Neutral merocyanine dyes: for in vivo NIR fluorescence imaging of amyloid-β plaques

2017 ◽  
Vol 53 (71) ◽  
pp. 9910-9913 ◽  
Author(s):  
Jin-wu Yan ◽  
Jia-ying Zhu ◽  
Kai-xiang Zhou ◽  
Jin-sheng Wang ◽  
Hui-ya Tan ◽  
...  

Two neutral merocyanine-based near-infrared fluorescent probes were for the first time developed through rational engineering of the classical cationic cyanine scaffold IR-780 for in vivo imaging of amyloid-β plaques.

2018 ◽  
Vol 183 (11) ◽  
pp. 354-354 ◽  
Author(s):  
Sophie Favril ◽  
Eline Abma ◽  
Francesco Blasi ◽  
Emmelie Stock ◽  
Nausikaa Devriendt ◽  
...  

One of the major challenges in surgical oncology is the intraoperative discrimination of tumoural versus healthy tissue. Until today, surgeons rely on visual inspection and palpation to define the tumoural margins during surgery and, unfortunately, for various cancer types, the local recurrence rate thus remains unacceptably high. Near-infrared (NIR) fluorescence imaging is an optical imaging technique that can provide real-time preoperative and intraoperative information after administration of a fluorescent probe that emits NIR light once exposed to a NIR light source. This technique is safe, cost-effective and technically easy. Several NIR fluorescent probes are currently studied for their ability to highlight neoplastic cells. In addition, NIR fluorescence imaging holds great promise for sentinel lymph node mapping. The aim of this manuscript is to provide a literature review of the current organic NIR fluorescent probes tested in the light of human oncology and to introduce fluorescence imaging as a valuable asset in veterinary oncology.


2021 ◽  
pp. 105167
Author(s):  
Yong Dae Park ◽  
Mayank Kinger ◽  
Changho Min ◽  
Sang Yeob Lee ◽  
Youngjoo Byun ◽  
...  

2016 ◽  
Vol 88 (3) ◽  
pp. 1944-1950 ◽  
Author(s):  
Hualong Fu ◽  
Peiyu Tu ◽  
Liu Zhao ◽  
Jiapei Dai ◽  
Boli Liu ◽  
...  

2021 ◽  
Author(s):  
Haoli Yu ◽  
Yuesong Wang ◽  
Yan Chen ◽  
Min Ji

Purpose: Near-infrared (NIR) fluorescence imaging (FI) become a research hotspot in the field of in vivo imaging. Here, we intend to synthesize a NIR-II fluorescence nano-system with an excellent fluorescence...


Nanoscale ◽  
2014 ◽  
Vol 6 (15) ◽  
pp. 9264-9272 ◽  
Author(s):  
Gary Sitbon ◽  
Sophie Bouccara ◽  
Mariana Tasso ◽  
Aurélie Francois ◽  
Lina Bezdetnaya ◽  
...  

Cadmium-free quantum dots doped with Mn2+ions show promising results forin vivobimodal MRI and NIR fluorescence imaging.


2017 ◽  
Vol 961 ◽  
pp. 112-118 ◽  
Author(s):  
Jia-ying Zhu ◽  
Lin-fu Zhou ◽  
Yu-kun Li ◽  
Shuo-bin Chen ◽  
Jin-wu Yan ◽  
...  

2012 ◽  
Vol 6 (1) ◽  
pp. 80-84 ◽  
Author(s):  
Toru Funayama ◽  
Masataka Sakane ◽  
Tetsuya Abe ◽  
Isao Hara ◽  
Eiichi Ozeki ◽  
...  

Marginal resection during resection of a spinal metastasis is frequently difficult because of the presence of important tissues such as the aorta, vena cava, and dura mater, including the spinal cord adjacent to the vertebral body. Thus, there is an urgent need for novel intraoperative imaging modalities with the ability to clearly identify bone metastasis. We have proposed a novel nanocarrier loaded with indocyanine green (ICG) (ICG-lactosome) with tumor selectivity attributable to its enhanced permeation and retention (EPR) effect. We studied its feasibility in intraoperative near-infrared (NIR) fluorescence diagnosis with ICG-lactosome for imaging spinal metastasis. A rat model of subcutaneous mammary tumor and a rat model of spinal metastasis of breast cancer were used. Fluorescence emitted by the subcutaneous tumors and the spinal metastasis were clearly detected for at least 24 h. Moreover, imaging of the dissected spine revealed clear fluorescence emitted by the metastatic lesion in the L6 vertebra while the normal bone lacked fluorescence. This study was the first report on NIR fluorescence imaging of spinal metastasis in vivo. NIR fluorescence imaging with ICG-lactosome could be an effective intraoperative imaging modality for detecting spinal metastasis.


2018 ◽  
Vol 115 (17) ◽  
pp. 4465-4470 ◽  
Author(s):  
Jessica A. Carr ◽  
Daniel Franke ◽  
Justin R. Caram ◽  
Collin F. Perkinson ◽  
Mari Saif ◽  
...  

Fluorescence imaging is a method of real-time molecular tracking in vivo that has enabled many clinical technologies. Imaging in the shortwave IR (SWIR; 1,000–2,000 nm) promises higher contrast, sensitivity, and penetration depths compared with conventional visible and near-IR (NIR) fluorescence imaging. However, adoption of SWIR imaging in clinical settings has been limited, partially due to the absence of US Food and Drug Administration (FDA)-approved fluorophores with peak emission in the SWIR. Here, we show that commercially available NIR dyes, including the FDA-approved contrast agent indocyanine green (ICG), exhibit optical properties suitable for in vivo SWIR fluorescence imaging. Even though their emission spectra peak in the NIR, these dyes outperform commercial SWIR fluorophores and can be imaged in the SWIR, even beyond 1,500 nm. We show real-time fluorescence imaging using ICG at clinically relevant doses, including intravital microscopy, noninvasive imaging in blood and lymph vessels, and imaging of hepatobiliary clearance, and show increased contrast compared with NIR fluorescence imaging. Furthermore, we show tumor-targeted SWIR imaging with IRDye 800CW-labeled trastuzumab, an NIR dye being tested in multiple clinical trials. Our findings suggest that high-contrast SWIR fluorescence imaging can be implemented alongside existing imaging modalities by switching the detection of conventional NIR fluorescence systems from silicon-based NIR cameras to emerging indium gallium arsenide-based SWIR cameras. Using ICG in particular opens the possibility of translating SWIR fluorescence imaging to human clinical applications. Indeed, our findings suggest that emerging SWIR-fluorescent in vivo contrast agents should be benchmarked against the SWIR emission of ICG in blood.


2002 ◽  
Vol 1 (4) ◽  
pp. 153535002002213
Author(s):  
Atif Zaheer ◽  
Thomas E. Wheat ◽  
John V. Frangioni

The detection of human malignancies by near-infrared (NIR) fluorescence will require the conjugation of cancer-specific ligands to NIR fluorophores that have optimal photoproperties and pharmacokinetics. IRDye78, a tetra-sulfonated heptamethine indocyanine NIR fluorophore, meets most of the criteria for an in vivo imaging agent, and is available as an N-hydroxysuccinimide ester for conjugation to low-molecular-weight ligands. However, IRDye78 has a high charge-to-mass ratio, complicating purification of conjugates. It also has a potentially labile linkage between fluorophore and ligand. We have developed an ion-pairing purification strategy for IRDye78 that can be performed with a standard C18 column under neutral conditions, thus preserving the stability of fluorophore, ligand, and conjugate. By employing parallel evaporative light scatter and absorbance detectors, all reactants and products are identified, and conjugate purity is maximized. We describe reversible and irreversible conversions of IRDye78 that can occur during sample purification, and describe methods for preserving conjugate stability. Using seven ligands, spanning several classes of small molecules and peptides (neutral, charged, and/or hydrophobic), we illustrate the robustness of these methods, and confirm that IRDye78 conjugates so purified retain bioactivity and permit NIR fluorescence imaging of specific targets.


2019 ◽  
Vol 7 (31) ◽  
pp. 4751-4757 ◽  
Author(s):  
Hao Liu ◽  
Rebecca T. Marquez ◽  
Xiaoqing Wu ◽  
Ke Li ◽  
Shweta Vadlamani ◽  
...  

A novel NIR fluorescence imaging-based method for non-intrusive evaluation of tumor targeting of nanomedicines was established. The average tumor-targeting index (TTI) and area under TTI-time curve (AUTC) were established as the in vivo indicators.


Sign in / Sign up

Export Citation Format

Share Document